The Wnt/β-Catenin Pathway Attenuates Experimental Allergic Airway Disease

Sebastian Reuter(Johannes Gutenberg University Mainz), Christian Taube(Ruhrlandklinik), A Heinz(Johannes Gutenberg University Mainz), Svetlana Ohngemach(Johannes Gutenberg University Mainz), Roland Buhl(Johannes Gutenberg University Mainz), Matthias Bros(University Medical Center of the Johannes Gutenberg University Mainz), Leonid Eshkind(Johannes Gutenberg University Mainz), Michael Stassen(University Medical Center of the Johannes Gutenberg University Mainz), Uğur Şahin(University Medical Center of the Johannes Gutenberg University Mainz), Evelyn Montermann(Johannes Gutenberg University Mainz), H Beckert(Johannes Gutenberg University Mainz), Helen Martin(University of Liverpool), Christina Belz(Johannes Gutenberg University Mainz)
The Journal of Immunology
June 16, 2014
10.4049/jimmunol.1400013
Cited by 49

Related Papers

mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
|Nature|2020|2k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
|Nature|2021|828
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
|Nature|2021|735
Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer 1 1The authors thank Professor T. K. Korhonen (Division of General Microbiology, University of Helsinki, Finland), who kindly donated Escherichia coli IH11165; Professor J.-F. Colombel (Laboratoire de Recherche sur les Maladies Inflammatoire de l’Intestine, Centre Hospitalier Universitaire, Lille, France) and Professor A. Darfeuille-Michaud (Faculte de Pharmacie, Clermont-Ferrand, France), who kindly donated the Crohn’s disease ileal isolates LF10 and LF82; and Dr. Keith Leiper (Gastroenterology Unit, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UK) for his cooperation in obtaining colorectal tissue specimens.As a consequence of the work described herein, a patent application has been filed by the University of Liverpool regarding the use of soluble plantain fiber in Crohn’s disease.
|Gastroenterology|2004|714